TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2331418
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine mixed with DTP vaccine
Study: 2331418
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine administered alone
Study: 27840069
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with the same first-line ACT
Study: 27840069
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with the same ACT
Study: 19291496
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) using the Modified Teaching Kids to Cope (MTKC)
Study: 17091022
Drug: Medication Managers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Managers (MM)
Study: 17091022
Drug: Medication Alarms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Alarms (ALR)
Study: 15303639
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (3 microg/kg)
Study: 15855578
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg nateglinide
Study: 11739446
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg glyburide
Study: 8101254
Drug: Sublingual oestradiol‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual oestradiol‐17 beta (1 mg)
Study: 3305189
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with vincristine, cytoxan, and prednisone (VCP)
Study: 3305189
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with vincristine, rubidazone, araC, and prednisone (VRAP)
Study: 21477047
Drug: Reinforcement-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement-based treatment (RBT)
Study: 9315991
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg quazepam
Study: 9315991
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg quazepam and 15 mg quazepam
Study: 29303859
Drug: Bovine bone
Normalized name: bovine bone preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine bone xenograft granules (0.25 to 1 mm of size, 1 mL/vial) with a resorbable pericardium membrane
Study: 19363850
Drug: Perindopril/indapamide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril/indapamide combination
Study: 19363850
Drug: Background antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background antihypertensive therapies
Study: 17203670
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy interventions (personal care, information, prescription of assistive devices, planning of discharge, reporting to primary care or community care)
Study: 17203670
Drug: No occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: No occupational therapy interventions (control group)
Study: 14601526
Drug: CpG‐7909 (ProMune)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CpG‐7909 (ProMune) in combination with rituximab (Rituxan) for non-Hodgkin's lymphoma
Study: 14601526
Drug: CpG‐7909 (ProMune)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CpG‐7909 (ProMune) as a vaccine adjuvant
Study: 1752712
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (650 mg ferrous sulfate; 130 mg elemental iron)
Study: 7039147
Drug: Feprazone 600
Normalized name: feprazone
DrugBank: Feprazone (DB13364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feprazone 600 mg
Study: 7039147
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg
Study: 25838001
Drug: Treatment adherence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment adherence (not using illicit opiates on top of prescribed opiates)
Study: 23846250
Drug: Surfactant (calfactant)
Normalized name: Calfactant
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surfactant (calfactant) administration (30 mg/cm height, up to three doses)
Study: 23846250
Drug: Surfactant (calfactant)
Normalized name: Calfactant
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surfactant (calfactant) administration
Study: 17203469
Drug: Thienopyridine pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienopyridine pretreatment with loading dose (group 1)
Study: 17203469
Drug: Thienopyridine pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienopyridine pretreatment without loading dose (group 2)
Study: 7950223
Drug: Jian Pi
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jian Pi Ling (JPL) tablet with retention‐enema of Radix Sophorae Flavescentis and Flos Sophora (RSF‐FS) decoction
Study: 28634365
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (clopidogrel plus aspirin) in patients with SBP ≥ 140 mmHg
Study: 28634365
Drug: Clopidogrel-aspirin in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-aspirin in patients with DBP ≥ 90 mmHg
Study: 28634365
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone in patients with SBP < 140 mmHg or DBP < 90 mmHg
Study: 23562341
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A (CsA), treated twice a day for 6 weeks
Study: 23562341
Drug: Placebo, treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, treated twice a day for 6 weeks
Study: 18476292
Drug: Intermittent antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent antiretroviral therapy (ART; drug conservation [DC] group])
Study: 16550574
Drug: Radiofrequency ablation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency ablation (RFA) combined with hepatic arterial infusion (HAI) chemotherapy (FUDR) for 6 months
Study: 8634735
Drug: Single-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intramuscular (IM) ceftriaxone sodium
Study: 8634735
Drug: 10-day oral
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day oral amoxicillin and clavulanate potassium
Study: 2049686
Drug: Diltiazem monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem monotherapy
Study: 2049686
Drug: Diltiazem-nitrate combination
Normalized name: organic nitrates in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem-nitrate combination
Study: 2049686
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate added to either monotherapy
Study: 6840166
Drug: Two well
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two well recognised treatment regimes
Study: 29936600
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia alone (group G)
Study: 22672578
Drug: Pulsed-dye laser
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-dye laser (PDL) treatment plus compression therapy (CT)
Study: 20382711
Drug: Serum VEGF-D
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum VEGF-D levels > 800 pg/mL
Study: 20382711
Drug: Serum VEGF-D
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum VEGF-D levels < 600 pg/mL
Study: 20382711
Drug: VEGF-D level
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF-D level > 600 pg/mL
Study: 9820884
Drug: Fluoride-containing formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-containing formulations (disodium monofluorophosphate and sodium fluoride)
Study: 186090
Drug: Propranolol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.3 mg/kg)
Study: 186090
Drug: Practolol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (1.0 mg/kg)
Study: 186090
Drug: Noradrenaline (vasoconstrictor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (vasoconstrictor doses) with propranolol or practolol
Study: 20495139
Drug: Phenylephrine 25
Normalized name: phenylephrine 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 25 μg/min
Study: 16606867
Drug: Aggressive risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive risk factor modification strategy (targeted treatment of hypertension, dyslipidaemia, homocysteine, haemoglobin and phosphate)
Study: 12568834
Drug: Tacrine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (initial dose of 40 mg/day increased up to 160 mg/day)
Study: 11342422
Drug: PMitCEBO (mitoxantrone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMitCEBO (mitoxantrone, 7 mg/m2 IV on day 1)
Study: 11342422
Drug: PAdriaCEBO (adriamycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAdriaCEBO (adriamycin, 35 mg/m2 IV on day 1)
Study: 7840553
Drug: Dapsone monotherapy
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone monotherapy (68 patients)
Study: 7840553
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dapsone and rifampin
Study: 7840553
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen (dapsone, rifampin, isoniazid, prothionamide)
Study: 3281706
Drug: 1% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% silver sulphadiazine ophthalmic ointment
Study: 31326593
Drug: Ropivacaine (2mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (2mL of 7.5mg/mL injected into the vestibular capsule before extraction)
Study: 31326593
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline solution injected into the vestibular capsule before extraction)
Study: 31144590
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy plus brachytherapy
Study: 31144590
Drug: Radical prostatectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical prostatectomy plus adjuvant radiation therapy
Study: 27284754
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein intake (HPI; 0.6 g•kg‐1•bolus‐1)
Study: 27284754
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein intake (MPI; 0.3 g•kg‐1•bolus‐1)
Study: 17712241
Drug: One-session HIV
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session HIV risk-reduction intervention during 16 weeks of outpatient cognitive behavioral SUD treatment
Study: 15121556
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 microg vaginally 6 to 8 hours after mifepristone 200 mg
Study: 15121556
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 microg vaginally 23 to 25 hours after mifepristone 200 mg
Study: 2525329
Drug: Nicorandil 5
Normalized name: nicorandil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 5 mg twice daily
Study: 2525329
Drug: Nicorandil 10
Normalized name: nicorandil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 10 mg twice daily
Study: 16513448
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (300 mL daily for 10 days)
Study: 16513448
Drug: Ritonavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (400 mg daily for 10 days)
Study: 16513448
Drug: Water (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (300 mL daily for 10 days)
Study: 8937535
Drug: Lamotrigine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (75 to 400 mg daily)
Study: 1569602
Drug: MTP‐PE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP‐PE 1 mg
Study: 1569602
Drug: MTP‐PE 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP‐PE 4 mg
Study: 31425441
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF), mean daily dose 927 ± 209 mg/m²
Study: 27221208
Drug: IV brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV brivaracetam (BRV) administered as a bolus (200 mg/day BID)
Study: 27221208
Drug: IV brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV brivaracetam (BRV) administered as an infusion (200 mg/day BID)
Study: 27221208
Drug: Oral brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral brivaracetam (BRV) (200 mg/day)
Study: 27221208
Drug: IV brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV brivaracetam (BRV) (bolus or infusion)
Study: 14555369
Drug: Medicine for
Normalized name: IBUPROFEN 200 mg ORAL TABLET [Ibuprofen Fast relief medicine for pain]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine for headache
Study: 14555369
Drug: Medicine for
Normalized name: IBUPROFEN 200 mg ORAL TABLET [Ibuprofen Fast relief medicine for pain]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine for stomach ache
Study: 14555369
Drug: Reported medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reported medicine use trend
Study: 14555369
Drug: Frequent users
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent users of medicine
Study: 8606475
Drug: Ibuprofen (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (three doses: 10 mg/kg intravenously followed by 5 mg/kg at 24 and 48 hours; n = 12)
Study: 8606475
Drug: Ibuprofen (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (one dose: 10 mg/kg intravenously; n = 11)
Study: 8606475
Drug: Ibuprofen (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (three doses)
Study: 6775327
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg d-amphetamine
Study: 21497767
Drug: l-carnitine 50
Normalized name: L-Carnitine 500mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine 50 mg/kg body weight PO
Study: 1312907
Drug: Glutathione (GSH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione (GSH, 2.5 g given i.v.) pretreatment prior to cisplatin infusion
Study: 1312907
Drug: Cisplatin (CDDP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (CDDP, 80 mg/m2) alone
Study: 1312907
Drug: Cisplatin (CDDP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (CDDP, 80 mg/m2) with GSH pretreatment
Study: 3899093
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg purified porcine relaxin vaginally applied on the day of embryo transfer and again 3 days later
Study: 3899093
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment outside the trial (not specified)
Study: 31613356
Drug: IGMKK16E7 low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IGMKK16E7 low-dose (0.5 g/day)
Study: 31613356
Drug: IGMKK16E7 middle-dose
Normalized name: WHEAT MIDDLINGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGMKK16E7 middle-dose (1 g/day)
Study: 31613356
Drug: IGMKK16E7 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGMKK16E7 high-dose (1.5 g/day)
Study: 19731310
Drug: Urodynamics (UDS)
Normalized name: sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urodynamics (UDS) treatment
Study: 19731310
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment based on symptoms alone
Study: 18786316
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin injection (MDI)
Study: 8676535
Drug: Oral meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meal
Study: 1611137
Drug: ponalrestat 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ponalrestat 600 mg per day
Study: 31116891
Drug: Subcutaneous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous oxytocin (4 µg/4 ml saline)
Study: 31116891
Drug: Subcutaneous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous lidocaine 1% (4 ml)
Study: 26265099
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) treatment
Study: 16088180
Drug: Dye-enhanced laser
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dye-enhanced laser ablation (DLA) using a low-power diode laser at 10 W with ICG concentration of 0.5 mg/ml.
Study: 12391535
Drug: Desflurane anaesthesia
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane anaesthesia supplemented by 2 mg tropisetron
Study: 10423055
Drug: Twice-daily morphine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily morphine sulphate controlled-release suppositories
Study: 10423055
Drug: Once-daily morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily morphine sulphate controlled-release suppositories
Study: 7582383
Drug: Oral methylergometrine
Normalized name: methylergometrine
DrugBank: Methylergometrine (DB00353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylergometrine (0.125 mg)
Study: 7582383
Drug: Intravenous methylergometrine
Normalized name: methylergometrine
DrugBank: Methylergometrine (DB00353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylergometrine (0.200 mg)
Study: 1648886
Drug: Ofloxacin administration
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin administration
Study: 21760499
Drug: Acetaminophen ER
Normalized name: acetaminophen Extended Release Oral Tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen ER 1300 mg
Study: 16022852
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of DMPA from a multidose vial (400 mg/mL)
Study: 16022852
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of DMPA from a single-unit-dose vial (150 mg/mL)
Study: 16022852
Drug: Unit-dose group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unit-dose group
Study: 12221311
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention (culturally sensitive group program in addition to individual supportive therapy)
Study: 12221311
Drug: Individual supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual supportive therapy (control group)
Study: 9697820
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg twice daily) with L‐NMMA (4 micromol/min)
Study: 8590530
Drug: Fibrate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrate therapy (gemfibrozil 900 mg/day, ciprofibrate 100 mg/day, bezafibrate 400 mg/day, fenofibrate 300 or 400 mg/day)
Study: 394300
Drug: Atropine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.6 mg) and meperidine (1 mg/kg body weight)
Study: 394300
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (benzocaine and intravenous diazepam only)
Study: 31108564
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care medication review (Control)
Study: 28771379
Drug: VR plus
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR plus standard treatment group
Study: 28771379
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) group
Study: 22260837
Drug: 3d triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3d triple therapy (rabeprazole 10mg + furazolidone 100mg + clarithromycin 250mg for 3 days)
Study: 22260837
Drug: 5d triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5d triple therapy (rabeprazole 10mg + furazolidone 100mg + clarithromycin 250mg for 5 days)
Study: 22260837
Drug: 7d triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7d triple therapy (rabeprazole 10mg + furazolidone 100mg + clarithromycin 250mg for 7 days)
Study: 19711845
Drug: Viferon (suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viferon (suppositories of human recombinant interferon alfa‐2)
Study: 19711845
Drug: Arbidol (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbidol (reference drug)
Study: 11219471
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg titrated to 80 mg titrated to 120 mg)
Study: 11219471
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg titrated to 100 mg)
Study: 9482510
Drug: Buflomedil 400
Normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil 400 mg intravenous daily for 5 days
Study: 3132275
Drug: Atropine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (30 micrograms/kg intravenous)
Study: 26377553
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity in daily living
Study: 23929355
Drug: multifaceted intervention:
Approvals — FDA: no, EMA: no, PMDA: no
Description: multifaceted intervention: team‐based supported employment, systematic medication management, and other behavioral health services